EU proposes changes to IP rules, legalizes generic drug production
Date: 2018-05-30   Author: Dhananjay Punekar  Category: #news

The European Commission has decided to make amendments in its intellectual property legislations in order to encourage pharmaceutical firms to manufacture generic medicines. The drug production would be slated for the nations where they are not covered under extended copyright protection.

The EU had introduced supplementary protection certificates that help in extending the duration of specific rights linked with the patents post their expiry period. The EC states that while these guidelines were initiated to support the research funding in Europe, many of the drug manufacturing firms are now looking towards production of generic drugs for non-European nations.

Sources cite that with the changes in the EU’s intellectual property laws, biosimilar firms in Europe will now be able to produce generic medicines in Europe and then export them to those regions where no laws related to copyright protection exist. Elzbieta Bienkowska, an EU Industry Commissioner, has announced that the move is aimed at generating a business of nearly ninety-five billion euros across the globe. She further added that EC took inspiration from Canada, where the strategy worked successfully and helped in the expansion of the pharma sector in the country in addition to offering jobs for the locals.

According to the EC, the proposal can generate net sales of nearly USD 1.2 billion each year after it receives approval from the European parliament as well twenty-eight-member countries of the EU. However, some of the original drug manufacturers have claimed that the decision can weaken the IP protection and can adversely impact the funding of the research activities in Europe.

The European Federation of Pharmaceutical Industries has raised concerns over the decision taken by the EC and has commented that the generic drug manufacturing waiver will pose a risk for the patient access to new therapies. But, the Medicines for Europe, representing generic drug manufacturers, has defended the decision of EU, emphasizing that it will help in the reduction of the medicine costs, thereby benefitting the Europe healthcare market.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Sirius Minerals inks massive polyhalite supply deal with Cibra Group
Author: Pankaj Singh

Sirius Minerals, the renowned U.K. based fertilizer development company, has recently announced its largest supply deal for its £3.2bn York Potash mine. According to sources familiar with the matter, the long-ter...


Agriculture Masterbatch Market to grow 6% CAGR over 2018 to 2024
Author: Rahul Varpe

As per reliable estimates, the Masterbatch Market for automotive sector is projected to surpass a CAGR of 5.8 percent over the next seven years. The consistent research and development activities being undert...


Polystyrene Acoustic Insulation Market to surpass $9bn by 2025
Author: Rahul Varpe

Acoustic Insulation Market size worth USD 10 billion in 2015, is predicted to touch USD 22 billion by 2025, recording a CAGR of 6% over the period of 2016-2025.” Acoustic insulation finds extensive application in construction and transportat...